BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc. (the “Company”) was held on June 20, 2018 for the purpose of: (1) electing two directors to serve for a term of three years and until a successor is duly elected and qualified; (2) ratifying the selection of Ernst&YoungLLP as the Company’s independent registered public accounting firm for 2018; and (3) holding an advisory vote approving the Company’s executive compensation.
The nominees for director were elected by the following votes:
|Nancy J. Hutson, Ph.D.||52,304,450||17,869,014|
|Robert A. Ingram||53,077,984||17,095,480|
In addition, there were 21,570,312 broker non-votes for each director.
The proposed ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2018 was approved by the following votes:
The proposed advisory resolution regarding executive compensation was approved by the following votes:
There was no other business voted upon at the Annual Meeting.
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.